Does Adjuvant Chemotherapy Dose Modification Have an Impact On the Outcome of Patients diagnosed with Advanced Stage Ovarian Cancer? An NRG Oncology/Gynecologic Oncology Group Study

PURPOSE: To determine the relationship between chemotherapy dose modification (dose adjustment or treatment delay), overall survival (OS) and progression-free survival (PFS) for women with advancedstage epithelial ovarian carcinoma (EOC) and primary peritoneal carcinoma (PPC) who receive carboplatin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Olawaiye, Alexander B., Java, James J., Krivak, Thomas C., Friedlander, Michael, Mutch, David G., Glaser, Gretchen, Geller, Melissa, O’Malley, David M., Wenham, Robert M., Lee, Roger B., Bodurka, Diane C., Herzog, Thomas J., Bookman, Michael A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6151871/
https://ncbi.nlm.nih.gov/pubmed/30135020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2018.07.021
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados